Wieslaw M. Kazmierski
Infectious Diseases Center for Excellence in Drug Discovery
GlaxoSmithKline
Five Moore Drive
Research Triangle Park
USA
Name/email consistency: high
- Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. Kazmierski, W.M., Aquino, C., Chauder, B.A., Deanda, F., Ferris, R., Jones-Hertzog, D.K., Kenakin, T., Koble, C.S., Watson, C., Wheelan, P., Yang, H., Youngman, M. J. Med. Chem. (2008)
- Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Kazmierski, W.M., Kenakin, T.P., Gudmundsson, K.S. Chemical. Biology. &. Drug. Design (2006)
- New, potent P1/P2-morpholinone-based HIV-protease inhibitors. Kazmierski, W.M., Furfine, E., Spaltenstein, A., Wright, L.L. Bioorg. Med. Chem. Lett. (2006)
- Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold. Kazmierski, W.M., Furfine, E., Gray-Nunez, Y., Spaltenstein, A., Wright, L. Bioorg. Med. Chem. Lett. (2004)
- Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties. Kazmierski, W.M., Andrews, W., Furfine, E., Spaltenstein, A., Wright, L. Bioorg. Med. Chem. Lett. (2004)
- Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety. Kazmierski, W.M., Bevans, P., Furfine, E., Spaltenstein, A., Yang, H. Bioorg. Med. Chem. Lett. (2003)
- Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease. Kazmierski, W.M., Furfine, E., Spaltenstein, A., Wright, L.L. Bioorg. Med. Chem. Lett. (2002)